Search
Latest topics
VISIT OUR PEGASISTER WEBSITES
http://mlpforums.forumotion
.com ---and---
www.chaosismagic.comThe most tagged keywords
Is curing patients a sustainable business model?
Is curing patients a sustainable business model?
https://arstechnica.com/tech-policy/2018/04/curing-disease-not-a-sustainable-business-model-goldman-sachs-analysts-say/
Analyst report notes that Gilead’s hep C cure will make less than $4 billion this year.
One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.
Analyst Salveen Richter and colleagues laid it out:
For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. In 2015, the company’s hepatitis C treatment sales peaked at $12.5 billion. But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. Goldman Sachs analysts estimate that the treatments will bring in less than $4 billion this year.
...........hmmm
Analyst report notes that Gilead’s hep C cure will make less than $4 billion this year.
One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.
Analyst Salveen Richter and colleagues laid it out:
Goldman Sachs wrote:The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.
For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. In 2015, the company’s hepatitis C treatment sales peaked at $12.5 billion. But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. Goldman Sachs analysts estimate that the treatments will bring in less than $4 billion this year.
Goldman Sachs wrote: “[Gilead]’s rapid rise and fall of its hepatitis C franchise highlights one of the dynamics of an effective drug that permanently cures a disease, resulting in a gradual exhaustion of the prevalent pool of patients,” the analysts wrote. The report noted that diseases such as common cancers—where the “incident pool remains stable”—are less risky for business.
...........hmmm
Trixie Lulamoon- Pony with a dream
- Posts : 276
Join date : 2015-07-07
Permissions in this forum:
You cannot reply to topics in this forum
|
|
Wed Jun 21, 2023 2:02 pm by MyLittleCarouselPony
» Gif Link for Anime Gif
Sat Nov 12, 2022 5:01 pm by MyLittleCarouselPony
» Reconciliation, Part 1
Thu Oct 27, 2022 11:36 am by MyLittleCarouselPony
» Fans Critique
Sat Feb 20, 2021 6:39 pm by Xylo,TheCarouselPony
» Transgender plea
Tue Jan 12, 2021 1:42 pm by MyLittleCarouselPony
» Video of Interview
Sun Dec 20, 2020 11:07 am by Xylo,TheCarouselPony
» List of transgender anime,manga,and short stories
Fri Jul 24, 2020 1:51 pm by MyLittleCarouselPony
» THE CHAT THREAD
Mon Jun 15, 2020 9:28 pm by Trixie Lulamoon
» Anything and Everything
Thu Aug 01, 2019 1:23 pm by Xylo,TheCarouselPony